About Araclon
Araclon is a company based in Zaragoza (Spain) founded in 2004 was acquired by Grifols in March 2012.. Araclon has raised $11.16 million across 1 funding round from investors including Grifols and Viamed Salud. Araclon offers products and services including ABtest Service, ABtest-IA, ABtest-MS, and ABvac40. Araclon operates in a competitive market with competitors including Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
- Headquarter Zaragoza, Spain
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Araclon Biotech, S.L.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Araclon
Araclon offers a comprehensive portfolio of products and services, including ABtest Service, ABtest-IA, ABtest-MS, and ABvac40. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Service for early detection of amyloid peptides in plasma samples
Determines total and free Aβ40 and Aβ42 in plasma
Joint determination of Aβ1-40 and Aβ1-42 via mass spectrometry
Active immunotherapy against Aβ40 for Alzheimer's treatment
Funding Insights of Araclon
Araclon has successfully raised a total of $11.16M through 1 strategic funding round. The most recent funding activity was a Series A round of $11.16 million completed in June 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $11.2M
-
First Round
First Round
(01 Jun 2009)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2009 | Amount | Series A - Araclon | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Araclon
Araclon has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Grifols and Viamed Salud. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Hospital and healthcare services are delivered with advanced medical technology.
|
Founded Year | Domain | Location | |
|
Plasma-derived therapies are developed to treat multiple diseases.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Araclon
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Araclon
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Araclon Comparisons
Competitors of Araclon
Araclon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Biologics platform developed for intracellular delivery in rare diseases.
|
|
| domain | founded_year | HQ Location |
Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics.
|
|
| domain | founded_year | HQ Location |
T-cell-based therapies for autoimmune and degenerative diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Araclon
When was Araclon founded?
Araclon was founded in 2004 and raised its 1st funding round 5 years after it was founded.
Where is Araclon located?
Araclon is headquartered in Zaragoza, Spain. It is registered at Zaragoza, Aragon, Spain.
Is Araclon a funded company?
Araclon is a funded company, having raised a total of $11.16M across 1 funding round to date. The company's 1st funding round was a Series A of $11.16M, raised on Jun 01, 2009.
What does Araclon do?
Araclon Biotech, a spin-off from the University of Zaragoza is dedicated to the research and development of therapies and diagnostic methods for neurodegenerative disorders with the initial focus on Alzheimers disease (AD). It has developed and patented a treatment called ABVac which based on an active immunotherapy (vaccine) for amyloid beta peptides 40 and 42. It has also developed ABtest kit for the early detection of AD by identifying the beta-amyloid 40 and 42 peptides in blood. It is also working on developing a diagnostic test and therapy for Parkinsons disease. In March 2012, Grifols acquired 51 of the capital of Araclon Biotech and since then Araclon is working as its subsidiary.
Who are the top competitors of Araclon?
Araclon's top competitors include Alector, Intra-Cellular Therapies and Entrada Therapeutics.
What products or services does Araclon offer?
Araclon offers ABtest Service, ABtest-IA, ABtest-MS, and ABvac40.
Who are Araclon's investors?
Araclon has 2 investors. Key investors include Grifols, and Viamed Salud.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.